Zacks Investment Research upgraded shares of OpGen (NASDAQ:OPGN) from a hold rating to a buy rating in a research note released on Saturday morning, Zacks.com reports. The firm currently has $0.75 price objective on the medical research company’s stock.
According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “
Separately, Alliance Global Partners assumed coverage on OpGen in a research note on Friday, March 1st. They set a buy rating and a $2.30 price target for the company.
OpGen stock opened at $0.58 on Friday. OpGen has a 12 month low of $0.53 and a 12 month high of $2.90. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.32 and a quick ratio of 1.20. The company has a market cap of $5.06 million, a PE ratio of -0.26 and a beta of 1.05.
OpGen (NASDAQ:OPGN) last released its quarterly earnings results on Tuesday, February 26th. The medical research company reported ($0.47) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.09). OpGen had a negative return on equity of 232.38% and a negative net margin of 453.73%. As a group, sell-side analysts anticipate that OpGen will post -0.93 EPS for the current fiscal year.
In related news, CEO Evan/ Fa Jones purchased 417,000 shares of the business’s stock in a transaction dated Thursday, March 28th. The stock was acquired at an average price of $0.60 per share, for a total transaction of $250,200.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.10% of the stock is owned by corporate insiders.
A hedge fund recently bought a new stake in OpGen stock. Virtu Financial LLC acquired a new position in shares of OpGen Inc (NASDAQ:OPGN) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 115,918 shares of the medical research company’s stock, valued at approximately $70,000. Virtu Financial LLC owned 1.34% of OpGen at the end of the most recent reporting period. Hedge funds and other institutional investors own 5.47% of the company’s stock.
OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.
Recommended Story: What is dollar cost averaging (DCA)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.